Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
278.30M | 309.20M | 298.54M | 267.12M | 186.89M | Gross Profit |
120.89M | 130.38M | 112.63M | 103.34M | 63.27M | EBIT |
-195.50M | -135.67M | -135.54M | -96.85M | -53.92M | EBITDA |
-152.53M | -99.00M | -418.98M | -89.91M | -39.51M | Net Income Common Stockholders |
-189.30M | -134.70M | -465.26M | -128.56M | -58.47M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
65.59M | 91.83M | 121.91M | 233.47M | 293.24M | Total Assets |
392.71M | 574.14M | 691.24M | 1.26B | 422.54M | Total Debt |
221.65M | 266.11M | 235.26M | 197.23M | 188.12M | Net Debt |
156.06M | 174.28M | 113.36M | -36.24M | -105.12M | Total Liabilities |
322.72M | 439.35M | 479.63M | 573.10M | 265.35M | Stockholders Equity |
69.99M | 134.80M | 211.60M | 690.70M | 157.19M |
Cash Flow | Free Cash Flow | |||
-28.12M | -12.58M | -67.39M | -51.09M | -17.71M | Operating Cash Flow |
-8.82M | -185.00K | -53.90M | -38.52M | -7.60M | Investing Cash Flow |
-18.75M | -10.06M | -15.76M | -506.69M | -10.12M | Financing Cash Flow |
1.44M | -20.03M | -39.99M | 486.00M | 206.43M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | $724.79M | 13.00 | 9.10% | 7.41% | -2.69% | 61.73% | |
60 Neutral | $13.80B | 7.25 | -2.76% | 3.77% | 2.19% | -42.55% | |
52 Neutral | $58.05M | ― | -34.39% | ― | 18.20% | 50.14% | |
52 Neutral | $64.54M | ― | -14.44% | ― | -3.58% | 50.73% | |
50 Neutral | $119.20M | ― | 74.55% | 10.87% | -0.16% | 57.03% | |
45 Neutral | $113.93M | ― | -135.48% | ― | -12.77% | 19.71% | |
43 Neutral | $50.02M | ― | -98.64% | ― | -14.67% | 59.39% |
Cardlytics, Inc. announced that Bank of America has issued a non-renewal notice for their existing agreements, set to expire on July 31, 2025, with operations continuing until January 27, 2026. Despite the non-renewal, Cardlytics believes the impact on its financial results will be minimal due to potential new arrangements with Bank of America and growth from other financial partners. Additionally, Cardlytics amended its loan facility with Banc of California, extending the maturity date to April 15, 2028, while maintaining $60 million in unused borrowings.
Spark’s Take on CDLX Stock
According to Spark, TipRanks’ AI Analyst, CDLX is a Neutral.
Cardlytics’ overall stock score is low due to significant financial performance issues, including declining revenues and high leverage, compounded by weak technical indicators and poor valuation. Although the earnings call suggested potential for future improvements, current challenges overshadow these prospects, leading to a cautious outlook.
To see Spark’s full report on CDLX stock, click here.